{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T21:16:21Z","timestamp":1768338981582,"version":"3.49.0"},"reference-count":33,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The benefits of denosumab as an antiresorptive therapy and in reducing fragility fractures are well documented. However, its association with atypical femur fractures (AFFs), especially in the absence of prior bisphosphonate use, remains poorly understood and warrants further investigation. This case report presents a rare instance of bilateral AFFs in a 78-year-old bisphosphonate-na\u00efve patient with a history of long-term denosumab therapy for previous metastatic breast cancer. Management involved intramedullary nail fixation after initial presentation with a unilateral AFF and a recommendation to cease denosumab therapy. However, the patient subsequently experienced a contralateral periprosthetic AFF below a total hip implant 5 months thereafter and was treated with open reduction internal fixation. This case report highlights the critical need for orthopedic surgeons to maintain a high level of suspicion and vigilance in screening for impending AFFs, especially in patients with a prolonged history of denosumab therapy without prior bisphosphonate use. Furthermore, the growing report of such cases emphasizes the urgent need for comprehensive research aimed at refining treatment protocols that balance the therapeutic benefits of denosumab and its associated risks of AFFs.<\/jats:p>","DOI":"10.3390\/jcm13102785","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:16:45Z","timestamp":1715231805000},"page":"2785","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bilateral Atypical Femoral Fracture in a Bisphosphonate-Na\u00efve Patient with Prior Long-Term Denosumab Therapy: A Case Report of the Management Strategy and a Literature Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Kyle","family":"Auger","sequence":"first","affiliation":[{"name":"Division of Orthopaedic Trauma & Adult Reconstruction, Department of Orthopaedic Surgery, Cooperman Barnabas Medical Center\u2014RWJBarnabas Health, Livingston, NJ 07039, USA"},{"name":"Division of Orthopaedic Trauma & Adult Reconstruction, Department of Orthopaedic Surgery, Jersey City Medical Center\u2014RWJBarnabas Health, Jersey City, NJ 07302, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Orthopaedic Trauma & Adult Reconstruction, Department of Orthopaedic Surgery, Cooperman Barnabas Medical Center\u2014RWJBarnabas Health, Livingston, NJ 07039, USA"},{"name":"Division of Orthopaedic Trauma & Adult Reconstruction, Department of Orthopaedic Surgery, Jersey City Medical Center\u2014RWJBarnabas Health, Jersey City, NJ 07302, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6578-9804","authenticated-orcid":false,"given":"Ian S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Orthopaedic Trauma & Adult Reconstruction, Department of Orthopaedic Surgery, Cooperman Barnabas Medical Center\u2014RWJBarnabas Health, Livingston, NJ 07039, USA"},{"name":"Division of Orthopaedic Trauma & Adult Reconstruction, Department of Orthopaedic Surgery, Jersey City Medical Center\u2014RWJBarnabas Health, Jersey City, NJ 07302, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaclyn M.","family":"Jankowski","sequence":"additional","affiliation":[{"name":"Division of Orthopaedic Trauma & Adult Reconstruction, Department of Orthopaedic Surgery, Cooperman Barnabas Medical Center\u2014RWJBarnabas Health, Livingston, NJ 07039, USA"},{"name":"Division of Orthopaedic Trauma & Adult Reconstruction, Department of Orthopaedic Surgery, Jersey City Medical Center\u2014RWJBarnabas Health, Jersey City, NJ 07302, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank A.","family":"Liporace","sequence":"additional","affiliation":[{"name":"Division of Orthopaedic Trauma & Adult Reconstruction, Department of Orthopaedic Surgery, Cooperman Barnabas Medical Center\u2014RWJBarnabas Health, Livingston, NJ 07039, USA"},{"name":"Division of Orthopaedic Trauma & Adult Reconstruction, Department of Orthopaedic Surgery, Jersey City Medical Center\u2014RWJBarnabas Health, Jersey City, NJ 07302, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5240-6633","authenticated-orcid":false,"given":"Richard S.","family":"Yoon","sequence":"additional","affiliation":[{"name":"Division of Orthopaedic Trauma & Adult Reconstruction, Department of Orthopaedic Surgery, Cooperman Barnabas Medical Center\u2014RWJBarnabas Health, Livingston, NJ 07039, USA"},{"name":"Division of Orthopaedic Trauma & Adult Reconstruction, Department of Orthopaedic Surgery, Jersey City Medical Center\u2014RWJBarnabas Health, Jersey City, NJ 07302, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1302\/0301-620X.93B10.26924","article-title":"Long-Term Bisphosphonate Usage and Subtrochanteric Insufficiency Fractures: A Cause for Concern?","volume":"93-B","author":"Yoon","year":"2011","journal-title":"J. Bone Jt. Surg. Br. Vol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11914-018-0464-6","article-title":"Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures","volume":"16","author":"Starr","year":"2018","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Takahashi, M., Ozaki, Y., Kizawa, R., Masuda, J., Sakamaki, K., Kinowaki, K., Umezu, T., Kondoh, C., Tanabe, Y., and Tamura, N. (2019). Atypical Femoral Fracture in Patients with Bone Metastasis Receiving Denosumab Therapy: A Retrospective Study and Systematic Review. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6236-6"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s12282-016-0746-8","article-title":"Atypical Femoral Fracture after Receiving Antiresorptive Drugs in Breast Cancer Patients with Bone Metastasis","volume":"24","author":"Ota","year":"2017","journal-title":"Breast Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/17453674.2014.885355","article-title":"Atypical Fracture of the Femur in a Patient Using Denosumab\u2014A Case Report","volume":"85","author":"Schilcher","year":"2014","journal-title":"Acta Orthop."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e42869","DOI":"10.5812\/traumamon.42869","article-title":"Denosumab and Atypical Femoral Fractures: A Scoping Literature Review","volume":"23","author":"Ismail","year":"2017","journal-title":"Trauma Mon."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1007\/s00198-016-3607-6","article-title":"Denosumab Compared to Other Treatments to Prevent or Treat Osteoporosis in Individuals at Risk of Fracture: A Systematic Review and Meta-Analysis","volume":"27","author":"Beaudoin","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4172\/2165-7920.1000737","article-title":"Atypical Femoral Fracture in a Patient with Metastatic Breast Cancer during Denosumab Therapy","volume":"6","author":"Ohnaru","year":"2016","journal-title":"J. Clin. Case Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00774-014-0606-6","article-title":"Atypical Femoral Fracture in a Patient Treated with Denosumab","volume":"33","author":"Khow","year":"2015","journal-title":"J. Bone Miner. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.4158\/EP12367.CR","article-title":"A Case of an Unusual Subtrochanteric Fracture in a Patient Receiving Denosumab","volume":"19","author":"Paparodis","year":"2013","journal-title":"Endocr. Pract."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/17453674.2013.854668","article-title":"Atypical Femoral Fractures Bilaterally in a Patient Receiving Denosumab","volume":"85","author":"Drampalos","year":"2014","journal-title":"Acta Orthop."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bone.2013.12.027","article-title":"Bilateral Atypical Femoral Fractures in a Patient Prescribed Denosumab\u2014A Case Report","volume":"61","author":"Thompson","year":"2014","journal-title":"Bone"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00198-015-3355-z","article-title":"Simultaneous Bilateral Atypical Femoral Fracture in a Patient Receiving Denosumab: Case Report and Literature Review","volume":"27","author":"Selga","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00198-015-3354-0","article-title":"Recurrence of Bilateral Atypical Femoral Fractures Associated with the Sequential Use of Teriparatide and Denosumab: A Case Report","volume":"27","author":"Ramchand","year":"2016","journal-title":"Osteoporos. Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/RLU.0000000000001592","article-title":"Impending Atypical Femoral Fracture in Patients with Medullary Thyroid Cancer with Skeletal Metastasis Treated with Long-Term Bisphosphonate and Denosumab","volume":"42","author":"Koizumi","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"230949901772791","DOI":"10.1177\/2309499017727916","article-title":"Atypical Femoral Fracture Associated with Bone-Modifying Agent for Bone Metastasis of Breast Cancer: A Report of Two Cases","volume":"25","author":"Tateiwa","year":"2017","journal-title":"J. Orthop. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised Trial of Effect of Alendronate on Risk of Fracture in Women with Existing Vertebral Fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women with Postmenopausal Osteoporosis: A Randomized Controlled Trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of Risedronate on the Risk of Hip Fracture in Elderly Women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: Mechanism of Action and Role in Clinical Practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"ref_24","unstructured":"Ganesan, K., Goyal, A., and Roane, D. (2024). StatPearls, StatPearls Publishing."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar2167","article-title":"Role of RANKL Inhibition in Osteoporosis","volume":"9","author":"McClung","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"E542","DOI":"10.1503\/cmaj.160450","article-title":"Atypical Femoral Fracture","volume":"189","author":"Khan","year":"2017","journal-title":"CMAJ"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e10681","DOI":"10.1002\/jbm4.10681","article-title":"Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy\u2014A Registry-Based Cohort Study","volume":"6","author":"Bonel","year":"2022","journal-title":"JBMR Plus"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.bone.2013.02.004","article-title":"Proposed Pathogenesis for Atypical Femoral Fractures: Lessons from Materials Research","volume":"55","author":"Ettinger","year":"2013","journal-title":"Bone"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s00223-022-00952-6","article-title":"Bilateral Atypical Femur Fractures After Denosumab in a Bisphosphonate Naive Patient: A Case Report","volume":"111","author":"Goh","year":"2022","journal-title":"Calcif. Tissue Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11657-022-01166-x","article-title":"Atypical Femoral Fracture in a Bisphosphonate-Na\u00efve Patient on Denosumab for Osteoporosis","volume":"17","author":"Kumar","year":"2022","journal-title":"Arch. Osteoporos."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update","volume":"35","author":"Somerfield","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Wong, M.H.F., Stockler, M.R., and Pavlakis, N. (2012). Bisphosphonates and Other Bone Agents for Breast Cancer. Cochrane Database Syst. Rev., CD003474.","DOI":"10.1002\/14651858.CD003474.pub3"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00520-012-1694-2","article-title":"Use of Bisphosphonates in Metastatic Breast Cancer: Single Institution Review at the Dr. H. Bliss Murphy Cancer Centre","volume":"21","author":"Murphy","year":"2013","journal-title":"Support. Care Cancer"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/10\/2785\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:42:33Z","timestamp":1760107353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/10\/2785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["jcm13102785"],"URL":"https:\/\/doi.org\/10.3390\/jcm13102785","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}